Brian J. Anderson

Brian J. Anderson

Auto-generated profile, based on publicly available information

Brian J. Anderson

Assistant Professor of Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, 5036 Gates Building, Philadelphia, PA 19104, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2018 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
JRJohn P. Reilly
John P. Reilly
FWFan Wang
Fan Wang
TJTiffanie K. Jones
Tiffanie K. Jones
JPJessica A. Palakshappa
Jessica A. Palakshappa
BABrian J. Anderson
Brian J. Anderson
NMNuala J Meyer
Nuala J Meyer

18 March 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JHJoseph Hippensteel
Joseph Hippensteel
BABrian J. Anderson
Brian J. Anderson
JOJames E. Orfila
James E. Orfila
SMSarah A. McMurtry
Sarah A. McMurtry
RDRobert M. Dietz
Robert M. Dietz
ESEric P. Schmidt
Eric P. Schmidt
Septic patients frequently develop cognitive impairment that persists beyond hospital discharge. The impact of sepsis on electrophysiological and molecular determinants of learning is underexplored. We observed that mouse survivors of sepsis or endotoxemia experienced loss of hippocampal long-term potentiation (LTP), a brain-derived neurotrophic factor (BDNF)-mediated process responsible for spatial memory formation. Memory impairment occurred despite preserved hippocampal BDNF content and could be reversed by stimulation of BDNF signaling, suggesting the presence of a local BDNF inhibitor. Sepsis is associated with degradation of the endothelial glycocalyx, releasing heparan sulfate fragments (of sufficient size and sulfation to bind BDNF) into the circulation. Heparan sulfate fragments penetrated the hippocampal blood-brain barrier during sepsis and inhibited BDNF-mediated LTP. Glycoarray approaches demonstrated that heparan sulfate’s avidity for BDNF increased with sulfation at the 2-O-position of iduronic acid and N-position of glucosamine. Circulating heparan sulfate in endotoxemic mice and septic humans was enriched in 2-O- and N-sulfated disaccharides; furthermore, the presence of these sulfation patterns in the plasma of septic patients at intensive care unit (ICU) admission predicted persistent cognitive impairment 14 days after ICU discharge or at hospital discharge. Our findings indicate that circulating 2-O- and N-sulfated heparan sulfate fragments contribute to septic cognitive impairment.

1 January 2018 in Critical Care Medicine
Verified
Journal Article
Closed access
NMNuala J. Meyer
Nuala J. Meyer
JRJohn P. Reilly
John P. Reilly
BABrian J. Anderson
Brian J. Anderson
JPJessica A. Palakshappa
Jessica A. Palakshappa
TJTiffanie K. Jones
Tiffanie K. Jones
SOSteven M. Opal
Steven M. Opal
Objective: Plasma interleukin-1 beta may influence sepsis mortality, yet recombinant human interleukin-1 receptor antagonist did not reduce mortality in randomized trials. We tested for heterogeneity in the treatment effect of recombinant human interleukin-1 receptor antagonist by baseline plasma interleukin-1 beta or interleukin-1 receptor antagonist concentration. Design: Retrospective subgroup analysis of randomized controlled trial. Setting: Multicenter North American and European clinical trial. Patients: Five hundred twenty-nine subjects with sepsis and hypotension or hypoperfusion, representing 59% of the original trial population. Interventions: Random assignment of placebo or recombinant human interleukin-1 receptor antagonist × 72 hours. Measurements and Main Results: We measured prerandomization plasma interleukin-1 beta and interleukin-1 receptor antagonist and tested for statistical interaction between recombinant human interleukin-1 receptor antagonist treatment and baseline plasma interleukin-1 receptor antagonist or interleukin-1 beta concentration on 28-day mortality. There was significant heterogeneity in the effect of recombinant human interleukin-1 receptor antagonist treatment by plasma interleukin-1 receptor antagonist concentration whether plasma interleukin-1 receptor antagonist was divided into deciles (interaction p = 0.046) or dichotomized (interaction p = 0.028). Interaction remained present across different predicted mortality levels. Among subjects with baseline plasma interleukin-1 receptor antagonist above 2,071 pg/mL (n = 283), recombinant human interleukin-1 receptor antagonist therapy reduced adjusted mortality from 45.4% to 34.3% (adjusted risk difference, –0.12; 95% CI, –0.23 to –0.01), p = 0.044. Mortality in subjects with plasma interleukin-1 receptor antagonist below 2,071 pg/mL was not reduced by recombinant human interleukin-1 receptor antagonist (adjusted risk difference, +0.07; 95% CI, –0.04 to +0.17), p = 0.230. Interaction between plasma interleukin-1 beta concentration and recombinant human interleukin-1 receptor antagonist treatment was not statistically significant. Conclusions: We report a heterogeneous effect of recombinant human interleukin-1 receptor antagonist on 28-day sepsis mortality that is potentially predictable by plasma interleukin-1 receptor antagonist in one trial. A precision clinical trial of recombinant human interleukin-1 receptor antagonist targeted to septic patients with high plasma interleukin-1 receptor antagonist may be worthy of consideration.

1 January 2008
Verified
Book Chapter
Closed access
BABrian J. Anderson
Brian J. Anderson
CLChris Larkin
Chris Larkin
KGKip Guja
Kip Guja
JSJoel F. Schildbach
Joel F. Schildbach

1 October 2005 in Structure
Verified
Journal Article
Closed access
CLChris Larkin
Chris Larkin
SDSaumen Datta
Saumen Datta
MHMatthew J. Harley
Matthew J. Harley
BABrian J. Anderson
Brian J. Anderson
AEAlexandra Ebie
Alexandra Ebie
JSJoel F. Schildbach
Joel F. Schildbach

1 October 2018 in Journal of Critical Care
Verified
Journal Article
Closed access
JPJessica A. Palakshappa
Jessica A. Palakshappa
JRJohn P. Reilly
John P. Reilly
WSWilliam D. Schweickert
William D. Schweickert
BABrian J. Anderson
Brian J. Anderson
VKViviane Khoury
Viviane Khoury
NMNuala J. Meyer
Nuala J. Meyer